ADDEX THERAPEUTICS

ADDEX THERAPEUTICS

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; a... nd GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Addex Therapeutics_logo

Industry:
Company

Founded:
2002

Address:
Chemin Des Mines, 9, Geneva, Switzerland Zipcode 1202

Country:
Switzerland

Phone:
41 22 884 1555

Market Cap:
55.50M
Total Revenue:
3.88M
Total Assets:
20.18M
Total Cash:
18.7M

Subsidiaries: Addex Pharma SA · Addex Pharmaceuticals France SAS


Key Executives
Name Title Pay Year Born
Mr. Timothy Mark Dyer Co-Founder, CEO & Director 576,053$ 1968(52 years old)
Mr. Lénaic Teyssédou Head of Fin. N/A 1986(34 years old)
Dr. Jean-Philippe Rocher Ph.D. Head of Discovery - Chemistry N/A 1959(61 years old)
Dr. Robert Lütjens Head of Discovery - Biology N/A 1968(52 years old)
Dr. Roger G. Mills M.D. Chief Medical Officer & Director N/A 1957(63 years old)
Dr. Werner Henrichi Ph.D. Consultant N/A 1943(77 years old)



Financial & Stock
Company's stock symbol is ADXN.SW. Lastest price : 1.6300. Total volume :26.66k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.addextherapeutics.com

  • Host name: od-d1e2fa.infomaniak.ch
  • IP address: 83.166.152.52
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...
Loading ...


More informations about "Addex Therapeutics" on Search Engine

Addextherapeutics.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Addextherapeutics.com Clinical and Pre-Clinical Pipeline. Using our allosteric modulator platform and drug …

Addextherapeutics.com Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference …

Addextherapeutics.com Non-Executive Directors - Addex therapeutics :: EN

Addextherapeutics.com Addex Corporate Presentation Download; Financial Reports. 2020 Annual Report & …

Addextherapeutics.com Our capabilities. Addex has developed unique capabilities that have allowed to …

Addextherapeutics.com mGlu7 NAM for PTSD. mGlu7 NAM for the treatment of post-traumatic stress disorder …

Addextherapeutics.com Tim DyerCo-Founder, Board Director and Chief Executive Officer. Roger MillsBoard …

Addextherapeutics.com Careers. Biology Department: Research Assistant Position - No PhD Candidates …

Addextherapeutics.com SEC Filings - Addex therapeutics :: EN

Addex therapeutics :: Overview

Addextherapeutics.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Addex Therapeutics Ltd (ADXN) Stock Price, News, Quote

Finance.yahoo.com About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule...

ADXN Stock Forecast, Price & News (Addex Therapeutics)

Marketbeat.com Nov 03, 2020 · Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The company can be reached via phone at 41 22 884 1555.

Addex therapeutics :: Research And Development

Addextherapeutics.com To date, our research and development efforts have been primarily focused on building a portfolio of proprietary drug candidates based on our allosteric modulator development capability. The allosteric modulator principle has broad applicability across a wide range of biological targets and therapeutic areas, but our primary focus is on G-protein coupled receptors, or GPCR, targets implicated ...

Addex Therapeutics | LinkedIn

Linkedin.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as...

Addex therapeutics :: Partners & Collaborations

Addextherapeutics.com Janssen Pharmaceuticals - The development of ADX71149 is part of a worldwide research collaboration and license agreement between Addex and Janssen Pharmaceuticals, Inc. to discover, develop and commercialize a novel mGluR2 PAM medication for the treatment of epilepsy, anxiety, schizophrenia and other undisclosed indications.

Addex Files Registration Statement on Form F-3 with the US

Globenewswire.com Apr 08, 2021 · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

Aditx Therapeutics, Inc. – Prolonging life and enhancing

Aditxt.com AditxtReprogramming™ Immune Reprogramming Technology. We are commercializing a nucleic acid-based technology named Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way the body naturally induces tolerance to our …

ADXN Stock Price | Addex Therapeutics Ltd. ADR Stock Quote

Marketwatch.com Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for...

Addex to Present at the 20th Annual Needham Virtual

Markets.businessinsider.com 1 day ago · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

Addex Therapeutics to Release Full-Year 2020 Financial

Globenewswire.com Mar 09, 2021 · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

Addex Therapeutics to Release Full-Year 2020 Financial

Finance.yahoo.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as...

Addex Successfully Completes $11.5 Million Capital

Finance.yahoo.com Jan 12, 2021 · Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based …

ADXN Stock Price Quote & News - Addex Therapeutics | Robinhood

Robinhood.com Addex Therapeutics Ltd American Depositary Shares, also called Addex Therapeutics, is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders.

Addex Therapeutics: Addex Therapeutics to Release Full

Bloomberg.com Mar 09, 2021 · Addex Therapeutics: Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021 March 9, 2021, 1:00 AM EST SHARE THIS ARTICLE

ADXN Addex Therapeutics Ltd Stock Quote - FINVIZ.com

Finviz.com Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.

Addex Therapeutics reports FY 2020 results (NASDAQ:ADXN)

Seekingalpha.com Mar 11, 2021 · Addex Therapeutics reports FY 2020 results Mar. 11, 2021 2:04 AM ET Addex Therapeutics Ltd (ADXN) By: Jignesh Mehta , SA News Editor Addex Therapeutics (NASDAQ: ADXN ) : FY GAAP EPS of -CHF0.48.

Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020

Seekingalpha.com Mar 11, 2021 · Ladies and gentlemen, welcome to the Webex Conference of Addex Therapeutics regarding the announcement of the Full Year 2020 Financial Results. At our customer's request this conference will be...

Addex Therapeutics: Addex to Present at the H.C

Bloomberg.com Mar 04, 2021 · About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an …

Addex Therapeutics - Crunchbase Company Profile & Funding

Crunchbase.com Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex ...

Addex Therapeutics Ltd. 2021 Foreign Issuer Report 6-K

Sec.report Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may ...

Addex Therapeutics: Addex Announces Pricing of $10.0

Bloomberg.com Jan 07, 2021 · About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an …

Addex Therapeutics to Release Full-Year 2020 Financial

Benzinga.com Mar 09, 2021 · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

Addex Therapeutics Company Profile: Stock Performance

Pitchbook.com Addex Therapeutics General Information Description. Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders.

ADDEX THERAPEUTICS LIMITED (ADDXF) Stock Price, News

Finance.yahoo.com Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021. Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage ...

Addex Therapeutics: Addex ADX71149 Receives IND Approval

Bloomberg.com Jan 21, 2021 · About Addex Therapeutics Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small ...

Addex Announces Pricing of $10.0 Million Global Offering

Ih.advfn.com About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non ...

Addex Therapeutics to Participate at the H.C. Wainwright

Finance.yahoo.com Sep 14, 2020 · About Addex Therapeutics. Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small ...

Addex Therapeutics Ltd ADR (ADXN) Recent Earnings

Earningswhispers.com Mar 11, 2021 · About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non ...

ADDXF - Addex Therapeutics Stock Competitors | MarketBeat

Marketbeat.com Addex Therapeutics has lower revenue, but higher earnings than Calithera Biosciences. Volatility & Risk. Calithera Biosciences has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Addex Therapeutics (SWX:ADXN) - Share price, News

Simplywall.st Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More Details

Form 6-K Addex Therapeutics Ltd. For: Jan 11

Streetinsider.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as...

Addex Therapeutics : GABAB Positive Allosteric Modulators

Marketscreener.com About Addex Therapeutics. Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non ...

Press Release : Addex to Present at the 20th Annual

Marketscreener.com 1 day ago · Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. (END) Dow Jones Newswires. April 13, 2021 01:00 ET (05:00 GMT) All news about ADDEX THERAPEUTICS LTD: 01:00a:

Addex Therapeutics : Janssen Gets FDA Approval to Begin

Marketscreener.com Addex Therapeutics Ltd. said its partner, Janssen Pharmaceuticals Inc., has received the U.S. Food and Drug Administration's Investigational New Drug approval to begin a Phase 2a proof of concept study for a treatment for patients with epilepsy.

Addex Therapeutics Company Profile - Office Locations

Craft.co Apr 06, 2020 · Addex Therapeutics, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant (ADX48621) for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and an ...

Addex Therapeutics News - ADXN | ADVFN

Ih.advfn.com Addex Therapeutics (ADXN) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

ADXN Addex Therapeutics Ltd - ADR — Stock Price and

Stocktwits.com Addex Therapeutics Ltd - ADR NASDAQ Updated Apr 7, 2021 7:59 PM. ADXN 10.65 0.15 (1.43%). 1,294

Addex Therapeutics Ltd 6-K Dec. 14, 2020 12:37 PM

Seekingalpha.com Dec 14, 2020 · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS

Markets.businessinsider.com Nov 02, 2020 · Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of …

Form 6-K Addex Therapeutics Ltd. For: Jan 21

Streetinsider.com Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as ...

ADDXF Stock | ADDEX THERAPEUTICS Stock Price Today

Markets.businessinsider.com Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators ...

Addex Therapeutics to Release Full-Year 2020 Financial

Tmcnet.com Mar 09, 2021 · About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non ...

Addex Therapeutics: Addex mGlu2 PAM Program to Advance

Bloomberg.com Jun 16, 2020 · About Addex Therapeutics Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small ...